(NASDAQ: LYEL) Lyell Immunopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.15%.
Lyell Immunopharma's earnings in 2025 is -$334,522,000.On average, 2 Wall Street analysts forecast LYEL's earnings for 2025 to be -$229,329,615, with the lowest LYEL earnings forecast at -$240,109,436, and the highest LYEL earnings forecast at -$218,549,794. On average, 2 Wall Street analysts forecast LYEL's earnings for 2026 to be -$229,477,284, with the lowest LYEL earnings forecast at -$233,316,672, and the highest LYEL earnings forecast at -$225,637,896.
In 2027, LYEL is forecast to generate -$200,829,541 in earnings, with the lowest earnings forecast at -$200,829,541 and the highest earnings forecast at -$200,829,541.